A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the objective response rate in patients with relapsed or
refractory Hodgkin's disease treated with MDX-060 in combination with gemcitabine or
gemcitabine alone.